Jos Houbiers Form 3 Summit Therapeutics / Jos Houbiers ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Houbiers Jos

(Last) (First) (Middle)

C/O SUMMIT THERAPEUTICS INC.,

ONE BROADWAY, 14TH FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/18/2020

3. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc. [ SMMT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	15,512(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(2)	10/19/2028	Common Stock	37,288	1.92	D
Stock Option (right to buy)	(3)	03/29/2029	Common Stock	44,000	1.79	D
Stock Option (right to buy)	(4)	07/08/2030	Common Stock	300,000	3.31	D
Stock Option (right to buy)	(5)	07/09/2030	Common Stock	20,000	3.17	D

Explanation of Responses:

1. Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Summit Therapeutics Inc., a Delaware corporation ("New Summit") to the attributes of Summit Therapeutics plc, a public limited company incorporated in England and Wales ("Old Summit"), the predecessor issuer. The succession occurred following the effectiveness, on September 18, 2020, of a United Kingdom court-approved scheme of arrangement in which every five ordinary shares, 0.01 pound sterling par value per share, of Old Summit were exchanged for one share of common stock, $0.01 par value per share, of New Summit, which resulted in New Summit becoming the holding company of Old Summit and its subsidiaries.

2. The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date.

3. The option was granted on March 29, 2019. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date.

4. The option was granted on July 8, 2020. The shares underlying the option are scheduled to vest in four equal annual installments with the first installment occurring on the one year anniversary of the grant date, subject to the satisfaction of certain performance targets.

5. The option was granted on July 9, 2020. The shares underlying the option are scheduled to vest in four equal annual installments with the first installment occurring on the one year anniversary of the grant date, subject to the satisfaction of certain performance targets.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Michael Paul Donaldson, Attorney-in-Fact	09/18/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.